These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 28557976)

  • 41. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
    Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
    Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gene alterations involving the CRLF2-JAK pathway and recurrent gene deletions in Down syndrome-associated acute lymphoblastic leukemia in Japan.
    Hanada I; Terui K; Ikeda F; Toki T; Kanezaki R; Sato T; Kamio T; Kudo K; Sasaki S; Takahashi Y; Hayashi Y; Inukai T; Kojima S; Koike K; Kosaka Y; Kobayashi M; Imaizumi M; Mitsui T; Hori H; Hara J; Horibe K; Nagai J; Goto H; Ito E
    Genes Chromosomes Cancer; 2014 Nov; 53(11):902-10. PubMed ID: 25044358
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic Effect of CD20 Expression in Adult B-cell Acute Lymphoblastic Leukemia.
    Esteban RE; Christianne B; Alvaro A; Demichelis-Gómez R
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):361-367. PubMed ID: 29544762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia.
    Feng J; Li Y; Jia Y; Fang Q; Gong X; Dong X; Ru K; Li Q; Zhao X; Liu K; Wang M; Tian Z; Jia Y; Wang Y; Lin D; Wei H; Tang K; Mi Y; Wang J
    J Hematol Oncol; 2017 Feb; 10(1):61. PubMed ID: 28245838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma.
    Sreedharanunni S; Singla S; Balakrishnan A; Singh A; Jamwal M; Singh N; Singh C; Jandial A; Lad D; Sharma P; Sachdeva MUS; Malhotra P; Das R
    Pathology; 2024 Jun; 56(4):556-564. PubMed ID: 38413253
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan.
    Imamura T; Kiyokawa N; Kato M; Imai C; Okamoto Y; Yano M; Ohki K; Yamashita Y; Kodama Y; Saito A; Mori M; Ishimaru S; Deguchi T; Hashii Y; Shimomura Y; Hori T; Kato K; Goto H; Ogawa C; Koh K; Taki T; Manabe A; Sato A; Kikuta A; Adachi S; Horibe K; Ohara A; Watanabe A; Kawano Y; Ishii E; Shimada H
    Blood Cancer J; 2016 May; 6(5):e419. PubMed ID: 27176795
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia (ALL).
    Addeo R; Caraglia M; Baldi A; D'Angelo V; Casale F; Crisci S; Abbruzzese A; Vincenze B; Campioni M; Di Tullio MT; Indolfi P
    Cancer Biol Ther; 2005 Jan; 4(1):32-8. PubMed ID: 15684603
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differing Outcomes of Patients with High Hyperdiploidy and ETV6-RUNX1 Rearrangement in Korean Pediatric Precursor B Cell Acute Lymphoblastic Leukemia.
    Lee JW; Kim S; Jang PS; Chung NG; Cho B
    Cancer Res Treat; 2021 Apr; 53(2):567-575. PubMed ID: 33070555
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
    Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
    Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
    Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
    Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia.
    Agirre X; Román-Gómez J; Jiménez-Velasco A; Garate L; Montiel-Duarte C; Navarro G; Vázquez I; Zalacain M; Calasanz MJ; Heiniger A; Torres A; Minna JD; Prósper F
    Oncogene; 2006 Mar; 25(13):1862-70. PubMed ID: 16314841
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overexpression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in childhood acute lymphoblastic leukemia.
    Jia M; Zhao HZ; Shen HP; Cheng YP; Luo ZB; Li SS; Zhang JY; Tang YM
    Int J Lab Hematol; 2015 Oct; 37(5):631-40. PubMed ID: 25955539
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical relevance of T-cell receptor delta gene rearrangements in childhood B-precursor cell acute lymphoblastic leukaemia.
    Díaz MA; Garcia-Sanchez F; Vicario JL; Ramirez M; Balas A; Madero L
    Br J Haematol; 1997 Nov; 99(2):308-13. PubMed ID: 9375746
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.
    Bercovich D; Ganmore I; Scott LM; Wainreb G; Birger Y; Elimelech A; Shochat C; Cazzaniga G; Biondi A; Basso G; Cario G; Schrappe M; Stanulla M; Strehl S; Haas OA; Mann G; Binder V; Borkhardt A; Kempski H; Trka J; Bielorei B; Avigad S; Stark B; Smith O; Dastugue N; Bourquin JP; Tal NB; Green AR; Izraeli S
    Lancet; 2008 Oct; 372(9648):1484-92. PubMed ID: 18805579
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
    Yoda A; Yoda Y; Chiaretti S; Bar-Natan M; Mani K; Rodig SJ; West N; Xiao Y; Brown JR; Mitsiades C; Sattler M; Kutok JL; DeAngelo DJ; Wadleigh M; Piciocchi A; Dal Cin P; Bradner JE; Griffin JD; Anderson KC; Stone RM; Ritz J; Foà R; Aster JC; Frank DA; Weinstock DM
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):252-7. PubMed ID: 20018760
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia.
    Agarwal M; Bakhshi S; Dwivedi SN; Kabra M; Shukla R; Seth R
    Pediatr Blood Cancer; 2018 Jun; 65(6):e27001. PubMed ID: 29446543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
    Hertzberg L; Vendramini E; Ganmore I; Cazzaniga G; Schmitz M; Chalker J; Shiloh R; Iacobucci I; Shochat C; Zeligson S; Cario G; Stanulla M; Strehl S; Russell LJ; Harrison CJ; Bornhauser B; Yoda A; Rechavi G; Bercovich D; Borkhardt A; Kempski H; te Kronnie G; Bourquin JP; Domany E; Izraeli S
    Blood; 2010 Feb; 115(5):1006-17. PubMed ID: 19965641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.
    Stengel A; Kern W; Haferlach T; Meggendorfer M; Fasan A; Haferlach C
    Leukemia; 2017 Mar; 31(3):705-711. PubMed ID: 27680515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.